Dermatologic conditions seen in end-stage renal disease

Seminars in Dialysis

Volumn 22, Issue 1, 2009, Pages 45-55

  Cordova, Katharine B ^b   Oberg, Thomas J ^c   Malik, Mohsin ^d   Robinson Bostom, Leslie ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; HUMAN; PREVALENCE; RISK FACTOR; SKIN DISEASE; UNITED STATES;

DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY FAILURE, CHRONIC; PREVALENCE; RISK FACTORS; SKIN DISEASES; UNITED STATES;

EID: 60349114137     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2008.00534.x     Document Type: Article

References (70)

1. Saray Y, Seckin D, Bilezikci B : Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 20 : 679 688, 2006
2. Shuichi O, Kiichiro D, Hiroko S, Isei T, Okamoto H, Horio T : Treatment of acquired perforating dermatosis with narrowband ultraviolet B. J Am Acad Dermatol 50 : 892 894, 2004
3. Seok-Beom H, Jung-Hun P, Chun-Gyoo I, Nack-In K : Acquired perforating dermatosis in patients with chronic renal failure and diabetes mellitus. J Korean Med Sci 19 : 283 288, 2004
4. Satchell AC, Crotty K, Lee S : Reactive perforating collagenosis: a condition that may be underdiagnosed. Aust J Dermatol 42 : 284 287, 2001
5. Robinson-Bostom L, DiGiovanna JJ : Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol 43 : 975 986, 2000
6. Ohe S, Danno K, Sasaki H, Isei T, Okamoto H, Horio T : Treatment of acquired perforating dermatosis with narrowband ultraviolet B. J Am Acad Dermatol 50 : 892 894, 2005
7. Hoque SR, Ameen M, Holden CA : Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol. Br J Dermatol 154 : 759 762, 2006
8. Nebel R, Fielder E, Danz B, Marsch WC, Kreft B : Acquired perforating dermatosis associated with diabetes mellitus and renal insufficiency requiring dialysis. Dtsch Med Wochenshr 132 : 2624 2626, 2007
9. Poh-Fitzpatrick MB, Masullo AS, Grossman ME : Porphyria cutanea tarda associated with chronic renal disease and hemodialysis. Arch Dermatol 116 : 191 195, 1980
10. Sassa S : Modern diagnosis and management of the porphyries. Br J Haematol 135 : 281 292, 2006
11. Kauppinen R : Porphyrias. Lancet 365 : 241 252, 2005
12. Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E : Bullous dermatosis in end-stage renal failure: porphyria or pseudoporphyria. Am J Kidney Dis 34 : 155 160, 1999
13. Sheih S, Cohen JL, Lim HW : Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 42 : 645 652, 2000
14. Riccioni N, Donati G, Soldani S, Scatena P, Arcabasso GD : Treatment of hemodialysis-related porphyria cutanea tarda with small repeated phlebotomies. Nephron 46 : 125 127, 1987
15. Green JJ, Manders SM : Pseudoporphyria. J Am Acad Dermatol 44 : 1 8, 2001
16. Tremblay JF, Veilleux B : Pseudoporphyria associated with hemodialysis treated with N-acetylcysteine. J Am Acad Dermatol 49 : 1189 1190, 2003
17. Vadoud-Seyedi J, Dobbeleer G, Simonart T : Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol 142 : 580 581, 2000
18. Cooke NS, McKenna K : A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol 32 : 64 66, 2007
19. Fuleihan GE, Rubeiz N : Dermatologic manifestations of parathyroid-related disorders. Clin Dermatol 24 : 281 288, 2006
20. Rogers NM, Teuber DJO, Coates PTH : Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 20 : 150 157, 2007
21. Mazhar AR, Johnson RJ, Gillen D, Stivelman J, Ryan MJ, Davis CL, Stehman-Breen CO : Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60 : 324 332, 2001
22. Hanafusa T, Yamaguchi Y, Tani M, Umegaki N, Nishimura Y, Katayama I : Intractable wounds caused by calcific uremic arteriolopathy treated with bisphophonates. J Am Acad Dermatol 57 : 1021 1025, 2007
23. Hafner J, Keusch G, Wahl C, Sauter B, Hürlimann A, von Weizsäcker F, Krayenbühl M, Biedermann K, Brunner U, Helfenstein U, Burget G : Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 33 : 954 962, 1995
24. Weenig RH, Sewell LD, David MDP, McCarthy JT, Pittelkow MR : Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56 : 569 579, 2007
25. Budisavljevic MN, Cheek D, Ploth DW : Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7 : 978 982, 1996
26. Bazari H, Jaff MR, Mannstadt M, Yan S : Case records of the Massachusetts General Hospital, a 57-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med 356 : 1049 1057, 2007
27. London GM, Gue′ rin AP, Marchais SJ, Me′ tivier F, Pannier B, Adda H : Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 : 1731 1740, 2003
28. Braun J : Extraosseous calcification in patients with chronic renal failure - no escape? Nephrol Dial Transplant 20 : 2054 2059, 2005
29. Angelis M, Wong LL, Myers SA, Wong ML : Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122 : 1083 1089, 1997 discussion 1089-1990
30. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R : Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 4 : 1 22, 2005
31. Rivet JR, Lebbe C, Urena P, Cordoliani F, Martinez F, Baglin AC, Aubert P, Aractingi S, Ronco P, Fournier P, Janinet A : Cutaneous calcification in patients with end-stage renal disease. Arch Dermatol 142 : 900 906, 2006
32. Guldbakke KK, Khachemoune A : Calciphylaxis. Int J Dermatol 46 : 231 238, 2007
33. Weenig RH : Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kß. J Am Acad Dermatol 58 : 458 471, 2008
34. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL : A case control study of proximal calciphylaxis. Am J Kidney Dis 32 : 376 383, 1998
35. Arseculeratne G, Evans AT, Morley SM : Calciphylaxis - a topical overview. J Eur Acad Dermatol Venereol 20 : 493 502, 2006
36. Chan YL, Mahony JF, Turner JJ, Posen S : The vascular lesions associated with skin necrosis in renal disease. Br J Dermatol 109 : 85 95, 1983
37. Hafner J, Keusch G, Wahl C, Burg G : Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 27 : 137 143, 1998
38. Oh DH, Eulau D, Tokugawa A, McGuire JS, Kohler S : Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol 40 : 979 987, 1999
39. Ackermann F, Levy A, Daugas E, Schartz N, Riaux A, Derancourt C, Urena P, Lebbé C : Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 143 : 1336 1337, 2007
40. Weenig RH, Gibson LE, el-Azhary R : The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. Semin Cutan Med Surg 26 : 163 167, 2007
41. Cicone JS, Petronis JB, Embert CD, Spector DA : Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43 : 1104 1108, 2004
42. Duffy A, Schurr M, Warner T, Chen H : Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 13 : 96 102, 2006
43. Rodby RA : Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 18 : 431 434, 2005
44. Shiraishi M, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, Misumi S, Maekawa Y, Murayama T, Tomita M, Tomitaet K : Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) be etidronate disodium. Am J Kidney Dis 48 : 151 154, 2006
45. Cowper SE : Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007. Available at http://www.icnfdr.org, accessed August 8, 2008
46. Introcaso CE, Elenitsas R, Xu X, James WD : Periocular papules in nephrogenic systemic fibrosis. J Am Acad Dermatol 59 : 536 537, 2008
47. Centers for Disease Control and Prevention : Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56 : 137 141, 2007
48. Cowper SE, Bucala RL : Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25 : 358, 2003
49. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R : Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36 : 208 210, 2004
50. Grobner T : Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104 1108, 2006
51. Marckman P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS : Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 : 2359 2362, 2006
52. Moreno-Romero JA, Segura S, Mascaro JM, Cowper SE, Julia M, Poch E, Botey A, Herrero C : Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetological factor. Br J Dermatol 157 : 783 787, 2007
53. U.S. Food and Drug Administration. Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). Available at http://www.fda.gov/cder/drug/infopage/gcca/ default.htm, accessed January 1, 2008
54. Perazella MA, Rodby RA : Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20 : 179 185, 2007
55. Knopp EA, Cowper SE : Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 21 : 123 128, 2008
56. Edward M, Quinn JA, Mukherjee S, Jensen M-BV, Jardine AG, Mark PB, Burden AD : Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214 : 584 593, 2008
57. Boyd AS, Zic JA, Abraham JL : Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 : 27 30, 2007
58. High WA, Ayers RA, Cowper SE : Research Letter. J Am Acad Dermatol 56 : 710 712, 2007
59. Kelly B, Petitt M, Sanchez R : Nephrogenic systemic fibrosis is associated with transforming growth factor B and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 58 : 1025 1030, 2008
60. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS : Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 : 3174 3178, 2007
61. Dawson P, Punwani S : Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. Semin Dial 21 : 160 165, 2008
62. Sieber MA, Pietsch H, Walter J, Haiden W, Frenzel T, Weinmann HJ : A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43 : 65 75, 2008
63. Pryor JG, Poggioli G, Galaria N, Gust A, Robinson J, Samei F, Hanjani NM, Scott GA : Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 57 : 105 111, 2007
64. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, Griffin MD, Leung N : Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 : 234 235, 2006
65. Goveia M, Chan BP, Patel PR : Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57 : 725 727, 2007
66. Saah G : Epoetin and nephrogenic systemic fibrosis. J Am Acad Dermatol 58 : 174 175, 2008
67. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R : Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2 : 258 263, 2007
68. Kay J, High WA : Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58 : 2543 2548, 2008
69. Chandran S, Petersen J, Jacobs C, Florentino D, Doeden K, Lafayette RA : Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53 : 129 132, 2009
70. Perazella MA, Reilly RF : Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. Semin Dial 21 : 171 173, 2008